Case report: olaparib use in metastatic lung adenocarcinoma with BRCA2 pathogenic variant
Poly (ADP-ribose) polymerase (PARP) inhibitors have been approved in malignancies associated with germline BRCA1 or BRCA2 pathogenic variants, such as breast, ovarian, prostate, and pancreatic cancer. In malignancies not associated with germline BRCA1 or BRCA2 pathogenic variants, the therapeutic re...
Saved in:
Main Authors: | Soon, Jonathan Jian Hao, Chan, Sock Hoai, Tan, Daniel Shao Weng, Ngeow, Joanne, Chiang, Jianbang |
---|---|
Other Authors: | Lee Kong Chian School of Medicine (LKCMedicine) |
Format: | Article |
Language: | English |
Published: |
2023
|
Subjects: | |
Online Access: | https://hdl.handle.net/10356/169833 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Nanyang Technological University |
Language: | English |
Similar Items
-
Can EGFR-Tyrosine Kinase Inhibitors (TKI) Alone Without Talc Pleurodesis Prevent Recurrence of Malignant Pleural Effusion (MPE) in Lung Adenocarcinoma
by: Verma, Akash, et al.
Published: (2017) -
Rare subtypes of adenocarcinoma of the lung
by: Ou, S.-H.I., et al.
Published: (2014) -
How many adenocarcinoma lung cancers come from bronchioloalveolar carcinoma?
by: Wong, A.S., et al.
Published: (2014) -
RUNX3 downregulation in human lung adenocarcinoma is independent of p53, EGFR or KRAS status
by: Omar, M.F.M., et al.
Published: (2014) -
Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing
by: Nahar, Rahul, et al.
Published: (2018)